Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024 - Seite 2

Crinetics will also have a poster presentation with data from the Phase 3 PATHFNDR-2 study evaluating paltusotine in acromegaly patients who were medically untreated. Additionally, data from the Phase 3 PATHFNDR-1 study of previously treated acromegaly patients who switched to paltusotine from an injected somatostatin receptor ligand, including a new analysis of patient-reported symptoms, will be presented as a poster presentation. Data from the PATHFNDR program will be featured in a Science and Innovation Theater led by Dr. Kevin C.J. Yuen, of the Barrow Neurological Institute, on Saturday, June 1, 2024, titled “Paltusotine: A Novel, Investigational Oral Small Molecule Somatostatin Receptor Ligand for Acromegaly.” A third presentation from the paltusotine clinical program will be a poster showing long-term safety and efficacy updates from the Phase 2 ACROBAT Advance open-label extension study.

*Proposed international nonproprietary name under review

Additional details on the presentations are shown below:

Title:	Once Daily Oral Atumelnant (CRN04894) Induces Rapid and Profound Reductions of Androstenedione and 17-hydroxyprogesterone in Participants with Classical Congenital Adrenal Hyperplasia: Initial Results from a 12-Week, Phase 2, Open-Label Study
Date/Time:	June 3rd from 12:00 – 1:30 pm ET
Location:	Session P108 - Late-Breaking Poster Presentations - ENDOExpo PosterArea - BCEC
Title:	Atumelnant (CRN04894) Induces Rapid And Sustained Reductions In Serum And Urine Cortisol In Patients With ACTH-dependent Cushing Syndrome During A Phase 1b/2a, Single Center, 10-day, Inpatient, Open-label Study
Date/Time:	June 3rd from 12:00 – 1:30 pm ET
Location:	Session P108 - Late-Breaking Poster Presentations - ENDOExpo PosterArea - BCEC
Title:	Efficacy and Safety of Once-Daily Oral Paltusotine in Medically Untreated Patients With Acromegaly: Results from the Phase 3, Randomized, Placebo-Controlled PATHFNDR-2 Study
Date/Time:	June 3rd from 12:00 – 1:30 pm ET
Location:	Session P108 - Late-Breaking Poster Presentations - ENDOExpo PosterArea – BCEC
Title:	Use of the Acromegaly Symptom Diary (ASD) in a Phase 3, Placebo-Controlled Study of Once-Daily, Oral Paltusotine in Patients With Acromegaly Switched From Injected Octreotide or Lanreotide
Date/Time:	June 3rd from 12:00pm – 1:30 pm ET
Location:	Neuroendocrinology and Pituitary: Pituitary Tumors IV - ENDOExpo PosterArea - BCEC
Title:	Long-Term Safety and Efficacy of Once-Daily Oral Paltusotine in the Treatment of Patients With Acromegaly: Update From ACROBAT Advance
Date/Time:	June 3rd from 12:00 – 1:30 pm ET
Location:	Session P108 - Late-Breaking Poster Presentations - ENDOExpo PosterArea – BCEC

The poster presentations will be made available on the Crinetics website at the time of presentation in accordance with the ENDO embargo policy.